Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Spruce Biosciences (SPRB) EBIT (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed EBIT for 4 consecutive years, with -$11.1 million as the latest value for Q4 2025.

  • On a quarterly basis, EBIT rose 53.89% to -$11.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$36.5 million, a 34.97% increase, with the full-year FY2025 number at -$36.5 million, up 34.97% from a year prior.
  • EBIT was -$11.1 million for Q4 2025 at Spruce Biosciences, down from -$8.2 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$2.7 million in Q2 2025 to a low of -$24.1 million in Q4 2024.
  • A 4-year average of -$12.0 million and a median of -$11.8 million in 2022 define the central range for EBIT.
  • Peak YoY movement for EBIT: crashed 115.64% in 2024, then soared 73.18% in 2025.
  • Spruce Biosciences' EBIT stood at -$12.1 million in 2022, then rose by 7.81% to -$11.2 million in 2023, then plummeted by 115.64% to -$24.1 million in 2024, then soared by 53.89% to -$11.1 million in 2025.
  • Per Business Quant, the three most recent readings for SPRB's EBIT are -$11.1 million (Q4 2025), -$8.2 million (Q3 2025), and -$2.7 million (Q2 2025).